← Zymeworks Inc. (ZYME) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Zymeworks Inc. (ZYME)
Pharmaceutical Preparations · market cap $1.9B
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2027-06-15 (est.)Phase 3 · Futibatinibimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ZW25 | Phase 2 | Endometrial Cancer |
| Futibatinib | Phase 3 | Biliary Tract Neoplasms |
| Zanidatamab | Phase 2 | Breast Cancer |
Price & technical context
3-month
-1.3%
6-month
+0.1%
12-month
+52.0%
52-wk range
$16.46–$31.05
vs 50-day MA
-0.6%
vs 200-day MA
+3.4%
Realized vol
51.9%
Max drawdown
-45.7%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ZYME (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.